- Home
- PSNL vs XERS Comparison
PSNL vs XERS Comparison
Compare PSNL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | XERS |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNL | XERS |
|---|---|---|
| Price | $16.03 | $10.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $15.17 | $12.86 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,648,000.00 | $49,590,000.00 |
| Revenue This Year | $21.10 | $32.91 |
| Revenue Next Year | $30.66 | $23.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $4.96 | $5.25 |
| 52 Week High | $18.89 | $10.35 |
Technical Indicators
Market Signals| Indicator | PSNL | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 69.13 |
| Support Level | $15.96 | $7.15 |
| Resistance Level | $16.39 | N/A |
| Average True Range (ATR) | 0.38 | 0.52 |
| MACD | -0.09 | 0.12 |
| Stochastic Oscillator | 32.11 | 96.03 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.